Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 25.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,353 shares of the medical equipment provider's stock after purchasing an additional 3,681 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Zimmer Biomet were worth $1,939,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Dodge & Cox increased its holdings in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after acquiring an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Van ECK Associates Corp increased its holdings in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after acquiring an additional 218,688 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Zimmer Biomet by 7.6% during the fourth quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after buying an additional 167,435 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Trading Up 0.6%

ZBH traded up $0.55 during trading on Friday, hitting $92.47. 1,003,196 shares of the company's stock were exchanged, compared to its average volume of 1,801,629. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The stock has a 50 day moving average price of $97.95 and a 200 day moving average price of $104.14. The firm has a market cap of $18.30 billion, a P/E ratio of 20.78, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the company posted $1.94 earnings per share. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. Zimmer Biomet's payout ratio is currently 21.24%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent research reports. The Goldman Sachs Group lowered their price target on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Royal Bank of Canada lowered their price target on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Robert W. Baird lowered their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Morgan Stanley lowered their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $111.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.